Unraveling prion protein interactions with aptamers and other PrP-binding nucleic acids

International Journal of Molecular Sciences

Volumn 18, Issue 5, 2017, Pages

  Macedo, Bruno ^a   Cordeiro, Yraima ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Aptamers; Nucleic acids; Prion protein; SELEX (Systematic Evolution of Ligands by Exponential Enrichment)

Indexed keywords

AMYLOID PROTEIN; APTAMER; NUCLEIC ACID BINDING PROTEIN; OLIGONUCLEOTIDE; PRION PROTEIN; CARRIER PROTEIN; NUCLEIC ACID; PROTEIN BINDING; SINGLE STRANDED DNA;

BINDING ASSAY; DOT HYBRIDIZATION; ELECTRON MICROSCOPY; FLUORESCENCE ANALYSIS; GEL MOBILITY SHIFT ASSAY; HUMAN; ISOTHERMAL TITRATION CALORIMETRY; NONHUMAN; NORTHERN BLOTTING; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; REVIEW; ROENTGEN SPECTROSCOPY; SURFACE PLASMON RESONANCE; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; TITRIMETRY; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

AMYLOIDOGENIC PROTEINS; ANIMALS; APTAMERS, NUCLEOTIDE; CARRIER PROTEINS; DNA, SINGLE-STRANDED; HUMANS; NUCLEIC ACIDS; PRION DISEASES; PRION PROTEINS; PROTEIN BINDING; SELEX APTAMER TECHNIQUE;

EID: 85019932642     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18051023     Document Type: Review

References (123)

1. Prusiner, S.B. Nobel Prize Lecture: Prions. Proc. Natl. Acad. Sci. USA 1998, 95, 13363–13383. [CrossRef] [PubMed]
2. Aguzzi, A.; Lakkaraju, A.K.K. Cell Biology of Prions and Prionoids: A Status Report. Trends Cell Biol. 2016, 26, 40–51. [CrossRef] [PubMed]
3. Collinge, J. Prion diseases of humans and animals: Their causes and molecular basis. Annu. Rev. Neurosci. 2001, 24, 519–550. [CrossRef] [PubMed]
4. 121–231. Nature 1996, 382, 180–182. [CrossRef] [PubMed]
5. Knaus, K.J.; Morillas, M.; Swietnicki, W.; Malone, M.; Surewicz, W.K.; Yee, V.C. Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nat. Struct. Biol. 2001, 8, 770–774. [CrossRef] [PubMed]
6. Caughey, B.; Baron, G.S.; Chesebro, B.; Jeffrey, M. Getting a grip on prions: Oligomers, amyloids, and pathological membrane interactions. Annu. Rev. Biochem. 2009, 78, 177–204. [CrossRef] [PubMed]
7. Knowles, T.P.J.; Vendruscolo, M.; Dobson, C.M. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 2014, 15, 384–396. [CrossRef] [PubMed]
8. Guo, J.L.; Lee, V.M.Y. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 2014, 20, 130–138. [CrossRef] [PubMed]
9. Silva, J.L.; Cordeiro, Y. The “Jekyll and Hyde” Actions of Nucleic Acids on the Prion-like Aggregation of Proteins. J. Biol. Chem. 2016, 291, 15482–15490. [CrossRef] [PubMed]
10. Chiti, F.; Dobson, C.M. Protein Misfolding, Functional Amyloid, and Human Disease. Annu. Rev. Biochem. 2006, 75, 333–366. [CrossRef] [PubMed]
11. Uversky, V.N.; Dunker, A.K. Understanding protein non-folding. Biochim. Biophys. Acta Proteins Proteom. 2010, 1804, 1231–1264. [CrossRef] [PubMed]
12. Yen, C.-F.; Harischandra, D.S.; Kanthasamy, A.; Sivasankar, S. Copper-induced structural conversion templates prion protein oligomerization and neurotoxicity. Sci. Adv. 2016, 2, e1600014. [CrossRef] [PubMed]
13. Silva, J.L.; Gomes, M.P.; Vieira, T.C.; Cordeiro, Y. PrP interactions with nucleic acids and glycosaminoglycans in function and disease. Front. Biosci. 2010, 15, 132–150. [CrossRef]
14. Vieira, T.C.R.G.; Reynaldo, D.P.; Gomes, M.P.B.; Almeida, M.S.; Cordeiro, Y.; Silva, J.L. Heparin binding by murine recombinant prion protein leads to transient aggregation and formation of rna-resistant species. J. Am. Chem. Soc. 2011, 133, 334–344. [CrossRef] [PubMed]
15. Liu, C.; Zhang, Y. Nucleic acid-mediated protein aggregation and assembly. Adv. Protein Chem. Struct. Biol. 2011, 84, 1–40. [PubMed]
16. Supattapone, S. Elucidating the role of cofactors in mammalian prion propagation. Prion 2014, 8, 100–105. [CrossRef] [PubMed]
17. Critchley, P.; Kazlauskaite, J.; Eason, R.; Pinheiro, T.J.T. Binding of prion proteins to lipid membranes. Biochem. Biophys. Res. Commun. 2004, 313, 559–567. [CrossRef] [PubMed]
18. Deleault, N.R.; Harris, B.T.; Rees, J.R.; Supattapone, S. Formation of native prions from minimal components in vitro. Proc. Natl. Acad. Sci. USA 2007, 104, 9741–9746. [CrossRef] [PubMed]
19. Miller, M.B.; Wang, D.W.; Wang, F.; Noble, G.P.; Ma, J.; Woods, V.L.; Li, S.; Supattapone, S. Cofactor molecules induce structural transformation during infectious prion formation. Structure 2013, 21, 2061–2068. [CrossRef] [PubMed]
20. Soto, C. Prion hypothesis: The end of the controversy? Trends Biochem. Sci. 2011, 36, 151–158. [CrossRef] [PubMed]
21. Cordeiro, Y.; Machado, F.; Juliano, L.; Juliano, M.A.; Brentani, R.R.; Foguel, D.; Silva, J.L. DNA Converts Cellular Prion Protein into the β-Sheet Conformation and Inhibits Prion Peptide Aggregation. J. Biol. Chem. 2001, 276, 49400–49409. [CrossRef] [PubMed]
22. Adler, V.; Zeiler, B.; Kryukov, V.; Kascsak, R.; Rubenstein, R.; Grossman, A. Small, highly structured RNAs participate in the conversion of human recombinant PrPSen to PrPRes in vitro. J. Mol. Biol. 2003, 332, 47–57. [CrossRef]
23. Deleault, N.R.; Lucassen, R.W.; Supattapone, S. RNA molecules stimulate prion protein conversion. Nature 2003, 425, 717–720. [CrossRef] [PubMed]
24. Macedo, B.; Millen, T.A.; Braga, C.A.C.A.; Gomes, M.P.B.; Ferreira, P.S.; Kraineva, J.; Winter, R.; Silva, J.L.; Cordeiro, Y. Nonspecific prion protein-nucleic acid interactions lead to different aggregates and cytotoxic species. Biochemistry 2012, 51, 5402–5413. [CrossRef] [PubMed]
25. Chaves, J.A.P.; Sanchez-López, C.; Gomes, M.P.B.; Sisnande, T.; Macedo, B.; de Oliveira, V.E.; Braga, C.A.C.; Rangel, L.P.; Silva, J.L.; Quintanar, L.; et al. Biophysical and morphological studies on the dual interaction of non-octarepeat prion protein peptides with copper and nucleic acids. J. Biol. Inorg. Chem. 2014, 19, 839–851. [CrossRef] [PubMed]
26. Zou, W.-Q.; Zheng, J.; Gray, D.M.; Gambetti, P.; Chen, S.G. Antibody to DNA detects scrapie but not normal prion protein. Proc. Natl. Acad. Sci. USA 2004, 101, 1380–1385. [CrossRef] [PubMed]
27. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249, 505–510. [CrossRef] [PubMed]
28. Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346, 818–822. [CrossRef] [PubMed]
29. Nandi, P.K. Interaction of prion peptide HuPrP106–126 with nucleic acid: Brief report. Arch. Virol. 1997, 142, 2537–2545. [CrossRef] [PubMed]
30. Nandi, P.K. Polymerization of human prion peptide HuPrP 106–126 to amyloid in nucleic acid solution. Arch. Virol. 1998, 143, 1251–1263. [CrossRef] [PubMed]
31. Nandi, P.K.; Leclerc, E. Polymerization of murine recombinant prion protein in nucleic acid solution. Arch. Virol. 1999, 144, 1751–1763. [CrossRef] [PubMed]
32. Cordeiro, Y.; Silva, J.L. The hypothesis of the catalytic action of nucleic acid on the conversion of prion protein. Protein Pept. Lett. 2005, 12, 251–255. [CrossRef] [PubMed]
33. Weiss, S.; Proske, D.; Neumann, M.; Groschup, M.H.; Kretzschmar, H.A.; Famulok, M.; Winnacker, E.L. RNA aptamers specifically interact with the prion protein PrP. J. Virol. 1997, 71, 8790–8797. [PubMed]
34. Lima, L.M.T.R.; Cordeiro, Y.; Tinoco, L.W.; Marques, A.F.; Oliveira, C.L.P.; Sampath, S.; Kodali, R.; Choi, G.; Foguel, D.; Torriani, I.; et al. Structural insights into the interaction between prion protein and nucleic acid. Biochemistry 2006, 45, 9180–9187. [CrossRef] [PubMed]
35. Mercey, R.; Lantier, I.; Maurel, M.C.; Grosclaude, J.; Lantier, F.; Marc, D. Fast, reversible interaction of prion protein with RNA aptamers containing specific sequence patterns. Arch. Virol. 2006, 151, 2197–2214. [CrossRef] [PubMed]
36. Cavaliere, P.; Pagano, B.; Granata, V.; Prigent, S.; Rezaei, H.; Giancola, C.; Zagari, A. Cross-talk between prion protein and quadruplex-forming nucleic acids: A dynamic complex formation. Nucleic Acids Res. 2013, 41, 327–339. [CrossRef] [PubMed]
37. Gabus, C.; Derrington, E.; Leblanc, P.; Chnaiderman, J.; Dormont, D.; Swietnicki, W.; Morillas, M.; Surewicz, W.K.; Marc, D.; Nandi, P.; et al. The Prion Protein Has RNA Binding and Chaperoning Properties Characteristic of Nucleocapsid Protein NCp7 of HIV-1. J. Biol. Chem. 2001, 276, 19301–19309. [CrossRef] [PubMed]
38. Guichard, C.; Ivanyi-Nagy, R.; Sharma, K.K.; Gabus, C.; Marc, D.; Mély, Y.; Darlix, J.L. Analysis of nucleic acid chaperoning by the prion protein and its inhibition by oligonucleotides. Nucleic Acids Res. 2011, 39, 8544–8558. [CrossRef] [PubMed]
39. Liu, M.; Yu, S.; Yang, J.; Yin, X.; Zhao, D. RNA and CuCl2 induced conformational changes of the recombinant ovine prion protein. Mol. Cell. Biochem. 2007, 294, 197–203. [CrossRef] [PubMed]
40. Gomes, M.P.B.; Millen, T.A.; Ferreira, P.S.; Cunha E Silva, N.L.; Vieira, T.C.R.G.; Almeida, M.S.; Silva, J.L.; Cordeiro, Y. Prion protein complexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells. J. Biol. Chem. 2008, 283, 19616–19625. [CrossRef] [PubMed]
41. Saborio, G.P.; Permanne, B.; Soto, C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001, 411, 810–813. [CrossRef] [PubMed]
42. Lucassen, R.; Nishina, K.; Supattapone, S. In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups. Biochemistry 2003, 42, 4127–4135. [CrossRef] [PubMed]
43. Cordeiro, Y.; Kraineva, J.; Gomes, M.P.B.; Lopes, M.H.; Martins, V.R.; Lima, L.M.T.R.; Foguel, D.; Winter, R.; Silva, J.L. The amino-terminal PrP domain is crucial to modulate prion misfolding and aggregation. Biophys. J. 2005, 89, 2667–2676. [CrossRef] [PubMed]
44. Strom, A.; Wang, G.S.; Picketts, D.J.; Reimer, R.; Stuke, A.W.; Scott, F.W. Cellular prion protein localizes to the nucleus of endocrine and neuronal cells and interacts with structural chromatin components. Eur. J. Cell. Biol. 2011, 90, 414–419. [CrossRef] [PubMed]
45. Mangé, A.; Crozet, C.; Lehmann, S.; Béranger, F. Scrapie-like prion protein is translocated to the nuclei of infected cells independently of proteasome inhibition and interacts with chromatin. J. Cell. Sci. 2004, 117, 2411–2416. [CrossRef] [PubMed]
46. Marijanovic, Z.; Caputo, A.; Campana, V.; Zurzolo, C. Identification of an intracellular site of prion conversion. PLoS Pathog. 2009, 5, e1000426. [CrossRef] [PubMed]
47. Yim, Y.-I.; Park, B.-C.; Yadavalli, R.; Zhao, X.; Eisenberg, E.; Greene, L.E. The multivesicular body is the major internal site of prion conversion. J. Cell. Sci. 2015, 1434–1443. [CrossRef] [PubMed]
48. Beaudoin, S.; Vanderperre, B.; Grenier, C.; Tremblay, I.; Leduc, F.; Roucou, X. A large ribonucleoprotein particle induced by cytoplasmic PrP shares striking similarities with the chromatoid body, an RNA granule predicted to function in posttranscriptional gene regulation. Biochim. Biophys. Acta Mol. Cell. Res. 2009, 1793, 335–345. [CrossRef] [PubMed]
49. Baron, G.S.; Magalhães, A.C.; Prado, M.A.M.; Caughey, B. Mouse-adapted scrapie infection of SN56 cells: Greater efficiency with microsome-associated versus purified PrP-res. J. Virol. 2006, 80, 2106–2117. [CrossRef] [PubMed]
50. Sc in cellsurface, raft-associated amyloid strings and webs. J. Cell. Biol. 2014, 204, 423–441. [CrossRef] [PubMed]
51. Qu, J.; Yu, S.; Zheng, Y.; Zheng, Y.; Yang, H.; Zhang, J. Aptamer and its applications in neurodegenerative diseases. Cell. Mol. Life Sci. 2017, 74, 683–695. [CrossRef] [PubMed]
52. Zhou, J.; Rossi, J. Aptamers as targeted therapeutics: Current potential and challenges. Nat. Rev. Drug Discov. 2017, 16, 181–202. [CrossRef] [PubMed]
53. Shangguan, D.; Li, Y.; Tang, Z.; Cao, Z.C.; Chen, H.W.; Mallikaratchy, P.; Sefah, K.; Yang, C.J.; Tan, W. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA 2006, 103, 11838–11843. [CrossRef] [PubMed]
54. Gogtay, N.J.; Sridharan, K. Therapeutic Nucleic Acids: Current clinical status. Br. J. Clin. Pharmacol. 2016, 82, 659–672.
55. L-Arginine Binder. J. Am. Chem. Soc. 1994, 116, 1698–1706. [CrossRef]
56. Lupold, S.E.; Hicke, B.J.; Lin, Y.; Coffey, D.S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002, 62, 4029–4033. [PubMed]
57. Tabarzad, M.; Jafari, M. Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins. Protein J. 2016, 35, 81–99. [CrossRef] [PubMed]
58. L-DNA ligand of vasopressin. Proc. Natl. Acad. Sci. USA 1997, 94, 11285–11290. [CrossRef] [PubMed]
59. Tang, Z.; Shangguan, D.; Wang, K.; Shi, H.; Sefah, K.; Mallikratchy, P.; Chen, H.W.; Li, Y.; Tan, W. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal. Chem. 2007, 79, 4900–4907. [CrossRef] [PubMed]
60. Yu, Y.; Liang, C.; Lv, Q.; Li, D.; Xu, X.; Lui, B.; Lu, A.; Zhang, G. Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers. Int. J. Mol. Sci. 2016, 17, 358. [CrossRef] [PubMed]
61. Marc, D. Aptamers to explore prion protein interactions with nucleic acids. Front. Biosci. 2010, 15, 550–563. [CrossRef]
62. Proske, D.; Gilch, S.; Wopfner, F.; Schatzl, H.M.; Winnacker, E.L.; Famulok, M. Prion-protein-specific aptamer reduces PrPSc formation. ChemBioChem 2002, 3, 717–725. [CrossRef]
63. Rhie, A.; Kirby, L.; Sayer, N.; Wellesley, R.; Disterer, P.; Sylvester, I.; Gill, A.; Hope, J.; James, W.; Tahiri-Alaoui, A. Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J. Biol. Chem. 2003, 278, 39697–39705. [CrossRef] [PubMed]
64. Kouassi, G.K.; Wang, P.; Sreevatan, S.; Irudayaraj, J. Aptamer-mediated magnetic and gold-coated magnetic nanoparticles as detection assay for prion protein assessment. Biotechnol. Prog. 2007, 23, 1239–1244. [CrossRef] [PubMed]
65. Sc show sequence and structure specificity. Exp. Biol. Med. 2006, 231, 204–214.
66. King, D.J.; Safar, J.G.; Legname, G.; Prusiner, S.B. Thioaptamer Interactions with Prion Proteins: Sequence-specific and Non-specific Binding Sites. J. Mol. Biol. 2007, 369, 1001–1014. [CrossRef] [PubMed]
67. Kocisko, D.A.; Vaillant, A.; Lee, K.S.; Arnold, K.M.; Bertholet, N.; Race, R.E.; Olsen, E.A.; Juteau, J.M.; Caughey, B. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob. Agents Chemother. 2006, 50, 1034–1044. [CrossRef] [PubMed]
68. Karpuj, M.V.; Giles, K.; Gelibter-Niv, S.; Scott, M.R.; Lingappa, V.R.; Szoka, F.C.; Peretz, D.; Denetclaw, W.; Prusiner, S.B. Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells. Mol. Med. 2007, 13, 190–198. [CrossRef] [PubMed]
69. Mashima, T.; Matsugami, A.; Nishikawa, F.; Nishikawa, S.; Katahira, M. Unique quadruplex structure and interaction of an RNA aptamer against bovine prion protein. Nucleic Acids Res. 2009, 37, 6249–6258. [CrossRef] [PubMed]
70. Burge, S.; Parkinson, G.N.; Hazel, P.; Todd, A.K.; Neidle, S. Quadruplex DNA: Sequence, topology and structure. Nucleic Acids Res. 2006, 34, 5402–5415. [CrossRef] [PubMed]
71. Murakami, K.; Nishikawa, F.; Noda, K.; Yokoyama, T.; Nishikawa, S. Anti-bovine prion protein RNA aptamer containing tandem GGA repeat interacts both with recombinant bovine prion protein and its beta isoform with high affinity. Prion 2008, 2, 73–80. [CrossRef] [PubMed]
72. Mashima, T.; Nishikawa, F.; Kamatari, Y.O.; Fujiwara, H.; Saimura, M.; Nagata, T.; Kodaki, T.; Nishikawa, S.; Kuwata, K.; Katahira, M. Anti-prion activity of an RNA aptamer and its structural basis. Nucleic Acids Res. 2013, 41, 1355–1362. [CrossRef] [PubMed]
73. Hayashi, T.; Oshima, H.; Mashima, T.; Nagata, T.; Katahira, M.; Kinoshita, M. Binding of an RNA aptamer and a partial peptide of a prion protein: Crucial importance of water entropy in molecular recognition. Nucleic Acids Res. 2014, 42, 6861–6875. [CrossRef] [PubMed]
74. Yakovchuk, P.; Protozanova, E.; Frank-Kamenetskii, M.D. Base-stacking and base-pairing contributions into thermal stability of the DNA double helix. Nucleic Acids Res. 2006, 34, 564–574. [CrossRef] [PubMed]
75. Olsthoorn, R.C.L. G-quadruplexes within prion mRNA: The missing link in prion disease? Nucleic Acids Res. 2014, 42, 9327–9333. [CrossRef] [PubMed]
76. Gabus, C.; Auxilien, S.; Péchoux, C.; Dormont, D.; Swietnicki, W.; Morillas, M.; Surewicz, W.; Nandi, P.; Darlix, J.L. The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein. J. Mol. Biol. 2001, 307, 1011–1021. [CrossRef] [PubMed]
77. Sayer, N.M.; Cubin, M.; Rhie, A.; Bullock, M.; Tahiri-Alaoui, A.; James, W. Structural Determinants of Conformationally Selective, Prion-binding Aptamers. J. Biol. Chem. 2004, 279, 13102–13109. [CrossRef] [PubMed]
78. Sekiya, S.; Nishikawa, F.; Noda, K.; Kumar, P.K.R.; Yokoyama, T.; Nishikawa, S. In vitro selection of RNA aptamers against cellular and abnormal isoform of mouse prion protein. Nucleic Acids Symp. Ser. 2005, 361–362. [CrossRef] [PubMed]
79. Sekiya, S.; Noda, K.; Nishikawa, F.; Yokoyama, T.; Kumar, P.K.R.; Nishikawa, S. Characterization and application of a novel RNA aptamer against the mouse prion protein. J. Biochem. 2006, 139, 383–390. [CrossRef] [PubMed]
80. Ogasawara, D.; Hasegawa, H.; Kaneko, K.; Sode, K.; Ikebukuro, K. Screening of DNA aptamer against mouse prion protein by competitive selection. Prion 2007, 1, 248–254. [CrossRef] [PubMed]
81. Bibby, D.F.; Gill, A.C.; Kirby, L.; Farquhar, C.F.; Bruce, M.E.; Garson, J.A. Application of a novel in vitro selection technique to isolate and characterise high affinity DNA aptamers binding mammalian prion proteins. J. Virol. Methods 2008, 151, 107–115. [CrossRef] [PubMed]
82. Sc. Exp. Biol. Med. 2011, 236, 466–476. [CrossRef] [PubMed]
83. Eisenberg, D.; Jucker, M. The amyloid state of proteins in human diseases. Cell 2012, 148, 1188–1203. [CrossRef] [PubMed]
84. Ylera, F.; Lurz, R.; Erdmann, V.A.; Fürste, J.P. Selection of RNA aptamers to the Alzheimer’s disease amyloid peptide. Biochem. Biophys. Res. Commun. 2002, 290, 1583–1588. [CrossRef] [PubMed]
85. Jucker, M.; Walker, L.C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013, 501, 45–51. [CrossRef] [PubMed]
86. Rahimi, F.; Murakami, K.; Summers, J.L.; Chen, C.H.B.; Bitan, G. RNA aptamers generated against oligomeric Aβ40 recognize common amyloid aptatopes with low specificity but high sensitivity. PLoS ONE 2009, 4, e7694. [CrossRef] [PubMed]
87. Rahimi, F.; Bitan, G. Selection of aptamers for amyloid β-protein, the causative agent of Alzheimer’s disease. J. Vis. Exp. 2010, 13, 1–7. [CrossRef] [PubMed]
88. Bitan, G.; Teplow, B. Preparation of Aggregate-Free, Low Molecular Weight Amyloid beta for Assembly and Toxicity Assays. Methods Mol. Biol. Protein 2005, 299, 3–9.
89. Pesarrodona, M.; Unzueta, U.; Vázquez, E. Dialysis: A characterization method of aggregation tendency. In Insoluble Proteins: Methods and Protocols; Springer: Berlin, Germany, 2014; pp. 321–330.
90. Hamada, H.; Arakawa, T.; Shiraki, K. Effect of additives on protein aggregation. Curr. Pharm. Biotechnol. 2009, 10, 400–407. [CrossRef] [PubMed]
91. Bunka, D.H.J.; Mantle, B.J.; Morten, I.J.; Tennent, G.A.; Radford, S.E.; Stockley, P.G. Production and characterization of RNA aptamers specific for amyloid fibril epitopes. J. Biol. Chem. 2007, 282, 34500–34509. [CrossRef] [PubMed]
92. Kayed, R.; Head, E.; Sarsoza, F.; Saing, T.; Cotman, C.W.; Necula, M.; Margol, L.; Wu, J.; Breydo, L.; Thompson, J.L.; et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2007, 2, 18. [CrossRef] [PubMed]
93. Kayed, R.; Glabe, C.G. Conformation-Dependent Anti-Amyloid Oligomer Antibodies. Methods Enzymol. 2006, 413, 326–344. [PubMed]
94. O’Nuallain, B.; Wetzel, R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. USA 2002, 99, 1485–1490. [CrossRef] [PubMed]
95. Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300, 486–489. [CrossRef] [PubMed]
96. Lambert, M.P.; Velasco, P.T.; Chang, L.; Viola, K.L.; Fernandez, S.; Lacor, P.N.; Khuon, D.; Gong, Y.; Bigio, E.H.; Shaw, P.; et al. Monoclonal antibodies that target pathological assemblies of Aβ. J. Neurochem. 2007, 100, 23–35. [CrossRef] [PubMed]
97. Lacor, P.N.; Buniel, M.C.; Chang, L.; Fernandez, S.J.; Gong, Y.; Viola, K.L.; Lambert, M.P.; Velasco, P.T.; Bigio, E.H.; Finch, C.E.; et al. Synaptic targeting by Alzheimer’s-related amyloid β oligomers. J. Neurosci. 2004, 24, 10191–10200. [CrossRef] [PubMed]
98. Lee, E.B.; Leng, L.Z.; Zhang, B.; Kwong, L.; Trojanowski, J.Q.; Abel, T.; Lee, V.M.Y. Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J. Biol. Chem. 2006, 281, 4292–4299. [CrossRef] [PubMed]
99. Cordeiro, Y.; Macedo, B.; Silva, J.L.; Gomes, M.P.B. Pathological implications of nucleic acid interactions with proteins associated with neurodegenerative diseases. Biophys. Rev. 2014, 6, 97–110. [CrossRef]
100. Calamai, M.; Taddei, N.; Stefani, M.; Ramponi, G.; Chiti, F. Relative Influence of Hydrophobicity and Net Charge in the Aggregation of Two Homologous Proteins. Biochemistry 2003, 42, 15078–15083. [CrossRef] [PubMed]
101. Chiti, F. Relative Importance of Hydrophobicity, Net Charge, and Secondary Structure Propensities in Protein Aggregation. Analysis 2004, 4, 43–59.
102. Sc -Like folding of recombinant PrP amyloids. J. Biol. Chem. 2015, 290, 1119–1128. [CrossRef] [PubMed]
103. Ginsberg, S.D.; Galvin, J.E.; Chiu, T.S.; Lee, V.M.Y.; Masliah, E.; Trojanowski, J.Q. RNA sequestration to pathological lesions of neurodegenerative diseases. Acta Neuropathol. 1998, 96, 487–494. [CrossRef] [PubMed]
104. Ginsberg, S.D.; Crino, P.B.; Hemby, S.E.; Weingarten, J.A.; Lee, V.M.Y.; Eberwine, J.H.; Trojanowski, J.Q. Predominance of neuronal mRNAs in individual Alzheimer’s disease senile plaques. Ann. Neurol. 1999, 45, 174–181. [CrossRef]
105. Marcinkiewicz, M. BetaAPP and furin mRNA concentrates in immature senile plaques in the brain of Alzheimer patients. J. Neuropathol. Exp. Neurol. 2002, 61, 815–829. [CrossRef] [PubMed]
106. Manuelidis, L. Nuclease resistant circular DNAs copurify with infectivity in scrapie and CJD. J. Neurovirol. 2011, 17, 131–145. [CrossRef] [PubMed]
107. Botsios, S.; Manuelidis, L. CJD and Scrapie Require Agent-Associated Nucleic Acids for Infection. J. Cell. Biochem. 2016, 117, 1947–1958. [CrossRef] [PubMed]
108. Simoneau, S.; Thomzig, A.; Ruchoux, M.-M.; Vignier, N.; Daus, M.L.; Poleggi, A.; Lebon, P.; Freire, S.; Durand, V.; Graziano, S.; et al. Synthetic Scrapie Infectivity: Interaction between Recombinant PrP and Scrapie Brain-Derived RNA. Virulence 2015, 6, 132–144. [CrossRef] [PubMed]
109. Hartl, F.U.; Bracher, A.; Hayer-Hartl, M. Molecular chaperones in protein folding and proteostasis. Nature 2011, 475, 324–332. [CrossRef] [PubMed]
110. Maury, C.P.J. Self-Propagating beta-sheet polypeptide structures as prebiotic informational molecular entities: The amyloid world. Orig. Life Evol. Biosph. 2009, 39, 141–150. [CrossRef] [PubMed]
111. Si, K. Prions: What Are They Good For? Annu. Rev. Cell. Dev. Biol 2015, 31, 149–169. [CrossRef] [PubMed]
112. Maury, C.P.J. The emerging concept of functional amyloid. J. Intern. Med. 2009, 265, 329–334. [PubMed]
113. Takahashi, T.; Tada, K.; Mihara, H. RNA aptamers selected against amyloid β-peptide (Aβ) inhibit the aggregation of Abeta. Mol. Biosyst. 2009, 5, 986–991. [PubMed]
114. Burchell, J.T.; Panegyres, P.K. Prion diseases: Immunotargets and therapy. ImmunoTargets Ther. 2016, 5, 57–68. [PubMed]
115. Cordeiro, Y.; Ferreira, N.C. New approaches for the selection and evaluation of anti-prion organic compounds. Mini Rev. Med. Chem. 2015, 15, 84–92. [PubMed]
116. Hanss, B.; Leal-Pinto, E.; Bruggeman, L.; Copeland, T.; Klotman, P. Identification and characterization of a cell membrane nucleic acid channel. Proc. Natl. Acad. Sci. USA 1998, 95, 1921–1926. [PubMed]
117. Reyes-Reyes, E.M.; Teng, Y.; Bates, P.J. A new paradigm for aptamer therapeutic AS1411 action: Uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010, 70, 8617–8629. [PubMed]
118. Cheng, C.; Chen, Y.H.; Lennox, K.A.; Behlke, M.A.; Davidson, B.L. In vivo SELEX for Identification of Brain-penetrating Aptamers. Mol. Ther. Nucleic Acids 2013, 2, E67. [PubMed]
119. Kim, Y.; Wu, Q.; Hamerlik, P.; Hitomi, M.; Sloan, A.E.; Barnett, G.H.; Weil, R.J.; Leahy, P.; Hjelmeland, A.B.; Rich, J.N. Aptamer identification of brain tumor-initiating cells. Cancer Res. 2013, 73, 4923–4936. [PubMed]
120. Xiao, S.J.; Hu, P.P.; Wu, X.D.; Zou, Y.L.; Chen, L.Q.; Peng, L.; Ling, J.; Zhen, S.J.; Zhan, L.; Li, Y.F.; et al. Sensitive discrimination and detection of prion disease-associated isoform with a dual-aptamer strategy by developing a sandwich structure of magnetic microparticles and quantum dots. Anal. Chem. 2010, 82, 9736–9742. [PubMed]
121. Zeiler, B.; Adler, V.; Kryukov, V.; Grossman, A. Concentration and removal of prion proteins from biological solutions. Biotechnol. Appl. Biochem. 2003, 37, 173–182. [PubMed]
122. Yu, P.; Zhang, X.; Xiong, E.; Zhou, J.; Li, X.; Chen, J. A label-free and cascaded dual-signaling amplified electrochemical aptasensing platform for sensitive prion assay. Biosens. Bioelectron. 2016, 85, 471–478. [CrossRef] [PubMed]
123. Zhou, J.; Battig, M.R.; Wang, Y. Aptamer-based molecular recognition for biosensor development. Anal. Bioanal. Chem. 2010, 398, 2471–2480. [CrossRef] [PubMed]